CG Pharmaceuticals has dosed the first subject in the Phase Ib/II maintenance clinical trial of ivaltinostat and capecitabine combination treatment for pancreatic adenocarcinoma (PDAC).

The trial will progress to enrol subjects in nearly 25 US institutions.

In the Phase Ib trial, the safety and tolerability of ivaltinostat will be analysed in three varying dose cohorts, enrolling locally advanced or metastatic PDAC patients who have received a minimum of one therapy previously. 

The Phase II trial will have metastatic PDAC patients without any evidence of disease progression following Folfirinox treatment.

Following randomisation, these subjects will be given either an ivaltinostat/capecitabine combination treatment or capecitabine as a single agent.

Analysing the impact of ivaltinostat on boosting progression-free survival (PFS) is the primary endpoint of the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Objective response rate (ORR), disease control rate (DCR), and overall survival (OS) are the trial’s key secondary endpoints.

A new anticancer treatment candidate, ivaltinostat hinders histone deacetylase’s enzymatic activity.

It was analysed for anticancer effects to treat metastatic PDAC and myelodysplastic syndrome.

According to findings from a Phase II trial in subjects with unresectable or metastatic PDAC who have not received any treatment previously, ivaltinostat offered DCR, ORR, and a median OS of 93.8%, 25%, and 10.8 months, respectively.

CG Pharmaceuticals CEO Dr Joong Myung Cho said: “Dosing of the first patient is a significant milestone for ivaltinostat as there is a great unmet medical need for the PDAC patients. 

“We are very excited about the start of this trial as ivaltinostat has demonstrated promising signs of efficacy from previous preclinical and clinical studies.”